Ebronucimab

伊努西单抗

Report date: 2026/03/15 20:00:14

Base Information

Drug NameEbronucimab
Drug Alias Name伊喜宁AK-102
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemiaHypercholesterolemia +[7] 
Global Approved IndicationsHypercholesterolemiaDyslipidemias
Approved Indications in ChinaHypercholesterolemiaDyslipidemias
Original Approved Country/TerritoryMainland China
Original Approved Date2024/09/26
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesZhongshan Akeso Biopharma Co LtdYabao Us Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAkeso Pharmaceuticals IncKang Rong Dongfang (Guangdong) Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHeterozygous familial hypercholesterolemiaHypercholesterolemiaHyperlipidemias +[6] 
Inactive IndicationsHomozygous familial hypercholesterolemia

Other Information

ATC CodeN/A
Related LinksN/A